New Day - New Shout Out...Researchers in every corner of the globe seem aware of what's going on. Hopefully we hear more from urological oncologists soon.
Minimal Functionalization of Ruthenium Compounds with Enhanced Photoreactivity against Hard-to-Treat Cancer Cells and Resistant Bacteria Gengela de Ftima Sousa Oliveira, Florencio Sousa Gouveia Jr., Alexandre Lopes Andrade, Mayron Alves de Vasconcelos, Edson Holanda Teixeira, Marcos V. Palmeira-Mello, Alzir A. Batista, Luiz Gonzaga de Frana Lopes, Idalina Maria Moreira de Carvalho, Eduardo Henrique Silva Sousa
Universidade Federal do Cear, Fortaleza, Brazil
Universidade Estadual do Cear, Itapipoca, Cear, Brazil
Universidade Federal de So Carlos, So Paulo, Brazil
ARTICLE July 23, 2024
Currently, a polypyridine ruthenium complex, TLD-1433, is in clinical trial phase II with promising treatment of nonmuscle invasive bladder cancer using PDT. Energy transfer is a key property of ruthenium complexes containing polypyridine ligands and anchored chromophores. Anthracene is an energy-donating chromophore that can transfer energy to a bipyridine ligand of the ruthenium complex upon light excitation. This energy transfer process can generate reactive oxygen species (ROS), such as singlet oxygen, which can damage DNA and proteins inside a tumor cell. Preclinical studies have shown that ruthenium complexes containing polypyridine ligands and anthracene exhibit antitumor activity in various tumor cell lines, including breast, prostate, and lung cancer opening broad opportunities for the development of new treatments. Beyond cancer therapy, photodynamic antimicrobial chemotherapy (PACT) has emerged with many opportunities considering the major threat of resistance that is faced globally. This issue has opened new avenues for systems first thought for cancer, and a series of properties have been investigated, including singlet oxygen photogeneration and DNA binding/cleavage, along with antimicrobial and cytotoxicity studies using cancer cell lines.